Designed and tested to combat the Ebola virus, remdesivir you are showing at this time one of the weapons with which doctors can fight the new coronavirus. Its use, as well as that of all the other molecules used, is “compassionate”: the drug, i.e., has not been studied to treat Covid-19, a disease never identified prior to the beginning of this year, but it is used for the treatment in the emergency of the individual patient in a serious condition and without any valid therapeutic alternatives because it has been shown in an empirical way to have some effectiveness. Experimentation Now, however, will be studied within a clinical trial, the first therapies for anti-Sars-Cov-2, from which you will be able to obtain useful data to understand how it acts and how it is effective. They have announced the health ministry and Gilead Sciences, the company that produces it, including the indication of the first centres in Italy will be involved: the Hospital Sacco of Milan, the ” Policlinico di Pavia, Azienda Ospedaliera of Padua, Azienda Ospedaliera Universitaria of Parma, and the National Institute for Infectious Diseases Lazzaro Spallanzani in Rome.
The medication “Remdesivir is one of the few drugs for which we have evidence of effectiveness, but only on models of the laboratory, in the case of coronaviruses,” explains Massimo Galli, Director of the Division of Clinical Infectious Diseases, AO-Polo Univ. Luigi Sacco. Before the emergence of these weeks, in fact, had been used against the outbreak of Mers, Middle East respiratory syndrome, also triggered by a coronavirus. “In the situation of total shortage of specific drugs, the use of the compassionate remdesivir has given a hope for the identification of a therapy that could be effective also in patients with infection by Sars-CoV-2”, goes on to the Gauls. “It is evident, however, that in patients with advanced infection is not easy to determine the degree of effectiveness in the context of compassionate use, then the data that will come from protocols of the clinical trial will be extremely important”. In other words, the goal is to have a standard therapy, determined on the basis of scientifically solid. The studies the Two studies undertaken to evaluate a different duration of treatment. Both will evaluate the effectiveness of remdesivir in two groups of patients, those with pneumonia caused by coronavirus associated with impairment of respiratory function and those with pneumonia but without alteration of the oxygen saturation. “This will enable us to determine with reasonable certainty the validity of the therapeutic approach also in patients without impairment in relation to the standard of care, that is, the other options at the moment we’re using,” concludes Galli. “What remdesivir is the first research protocol controlled which is implemented for the determination of the efficacy of a drug in this specific clinical condition”.
“The Republic will fight always in defense of the freedom of information, to its readers and to all those who have at heart the principles of democracy and civil coexistence”
Carlo Verdelli SUBSCRIBERS TO REPUBLIC © Reproduction reserved Today on offers of assistance, expressions of solidarity. Travel in Italy armored but more united as a Coronavirus, which is why the lethality in Italy is so high The doctor is sick: “I intubated and unconscious, now I’m back to life and to all I say: resist” The illegal immigrants of the infection The only border helpful
the Republic
